JP2006502378A - クロストリジウム毒素に関する細胞ベースの蛍光共鳴エネルギー転移(fret)アッセイ - Google Patents
クロストリジウム毒素に関する細胞ベースの蛍光共鳴エネルギー転移(fret)アッセイ Download PDFInfo
- Publication number
- JP2006502378A JP2006502378A JP2004540055A JP2004540055A JP2006502378A JP 2006502378 A JP2006502378 A JP 2006502378A JP 2004540055 A JP2004540055 A JP 2004540055A JP 2004540055 A JP2004540055 A JP 2004540055A JP 2006502378 A JP2006502378 A JP 2006502378A
- Authority
- JP
- Japan
- Prior art keywords
- substrate
- bont
- cell
- acceptor
- clostridial toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 231100001102 clostridial toxin Toxicity 0.000 title claims abstract description 342
- 238000003556 assay Methods 0.000 title claims description 28
- 238000002866 fluorescence resonance energy transfer Methods 0.000 title description 21
- 239000000758 substrate Substances 0.000 claims abstract description 558
- 238000000034 method Methods 0.000 claims abstract description 152
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 124
- 230000007017 scission Effects 0.000 claims abstract description 124
- 238000002165 resonance energy transfer Methods 0.000 claims abstract description 52
- 230000007888 toxin activity Effects 0.000 claims abstract description 52
- 238000000295 emission spectrum Methods 0.000 claims abstract description 41
- 238000000862 absorption spectrum Methods 0.000 claims abstract description 35
- 108030001720 Bontoxilysin Proteins 0.000 claims description 498
- 210000004027 cell Anatomy 0.000 claims description 369
- 239000000203 mixture Substances 0.000 claims description 141
- 239000000816 peptidomimetic Substances 0.000 claims description 130
- 210000002569 neuron Anatomy 0.000 claims description 107
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 claims description 106
- 108090000623 proteins and genes Proteins 0.000 claims description 94
- 102000004169 proteins and genes Human genes 0.000 claims description 87
- 229940124447 delivery agent Drugs 0.000 claims description 85
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 239000012634 fragment Substances 0.000 claims description 55
- 231100000765 toxin Toxicity 0.000 claims description 54
- 239000003053 toxin Substances 0.000 claims description 53
- 108700012359 toxins Proteins 0.000 claims description 53
- 229940053031 botulinum toxin Drugs 0.000 claims description 47
- 108010010469 Qa-SNARE Proteins Proteins 0.000 claims description 39
- 230000001105 regulatory effect Effects 0.000 claims description 31
- 239000012099 Alexa Fluor family Substances 0.000 claims description 26
- 150000001413 amino acids Chemical group 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 19
- 101000574352 Mus musculus Protein phosphatase 1 regulatory subunit 17 Proteins 0.000 claims description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 17
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 17
- 239000005090 green fluorescent protein Substances 0.000 claims description 17
- 206010029260 Neuroblastoma Diseases 0.000 claims description 16
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 15
- VHLZDSUANXBJHW-QWRGUYRKSA-N Gln-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHLZDSUANXBJHW-QWRGUYRKSA-N 0.000 claims description 14
- 230000005281 excited state Effects 0.000 claims description 14
- 210000002161 motor neuron Anatomy 0.000 claims description 14
- 241000700584 Simplexvirus Species 0.000 claims description 13
- 210000003169 central nervous system Anatomy 0.000 claims description 13
- 210000003594 spinal ganglia Anatomy 0.000 claims description 13
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 210000004748 cultured cell Anatomy 0.000 claims description 10
- 210000005260 human cell Anatomy 0.000 claims description 10
- 108091006116 chimeric peptides Proteins 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 210000000278 spinal cord Anatomy 0.000 claims description 9
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims description 8
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 claims description 8
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 claims description 8
- 230000002490 cerebral effect Effects 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 claims description 7
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 claims description 7
- CLSDNFWKGFJIBZ-YUMQZZPRSA-N Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O CLSDNFWKGFJIBZ-YUMQZZPRSA-N 0.000 claims description 7
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 7
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims description 7
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 7
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 claims description 7
- 108010056243 alanylalanine Proteins 0.000 claims description 7
- OPINTGHFESTVAX-BQBZGAKWSA-N Gln-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N OPINTGHFESTVAX-BQBZGAKWSA-N 0.000 claims description 6
- 108010047702 MPG peptide Proteins 0.000 claims description 6
- 210000002856 peripheral neuron Anatomy 0.000 claims description 6
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 claims description 5
- 239000004098 Tetracycline Substances 0.000 claims description 5
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 claims description 5
- 210000004295 hippocampal neuron Anatomy 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 239000013592 cell lysate Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 claims description 3
- 229940089093 botox Drugs 0.000 claims description 3
- 210000003618 cortical neuron Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 claims 1
- 102000050389 Syntaxin Human genes 0.000 claims 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 claims 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical group [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 claims 1
- 238000012546 transfer Methods 0.000 abstract description 22
- 239000000370 acceptor Substances 0.000 description 306
- 101000879393 Aplysia californica Synaptobrevin Proteins 0.000 description 103
- 235000018102 proteins Nutrition 0.000 description 72
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 description 42
- 241000282414 Homo sapiens Species 0.000 description 41
- 125000003275 alpha amino acid group Chemical group 0.000 description 39
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 33
- 230000000694 effects Effects 0.000 description 33
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 description 27
- 230000005284 excitation Effects 0.000 description 27
- 101000652315 Homo sapiens Synaptosomal-associated protein 25 Proteins 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 241000700159 Rattus Species 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 23
- 108010055044 Tetanus Toxin Proteins 0.000 description 22
- 102000053886 human SNAP25 Human genes 0.000 description 22
- 108010017743 Vesicle-Associated Membrane Protein 1 Proteins 0.000 description 21
- 102000004603 Vesicle-Associated Membrane Protein 1 Human genes 0.000 description 21
- 101000807882 Homo sapiens Vesicle-associated membrane protein 1 Proteins 0.000 description 20
- 101000639136 Homo sapiens Vesicle-associated membrane protein 2 Proteins 0.000 description 20
- 108010029485 Protein Isoforms Proteins 0.000 description 18
- 102000001708 Protein Isoforms Human genes 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 18
- 230000000670 limiting effect Effects 0.000 description 17
- 229940118376 tetanus toxin Drugs 0.000 description 17
- 108091005804 Peptidases Proteins 0.000 description 16
- 102000035195 Peptidases Human genes 0.000 description 16
- 239000002581 neurotoxin Substances 0.000 description 16
- 231100000618 neurotoxin Toxicity 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- -1 SNAP-25 Proteins 0.000 description 14
- 101710192266 Tegument protein VP22 Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 230000017854 proteolysis Effects 0.000 description 14
- 239000004365 Protease Substances 0.000 description 13
- 101000639133 Rattus norvegicus Vesicle-associated membrane protein 2 Proteins 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 235000019419 proteases Nutrition 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 241000287828 Gallus gallus Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 241000288906 Primates Species 0.000 description 12
- 101000807880 Mus musculus Vesicle-associated membrane protein 1 Proteins 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 10
- 101000807888 Bos taurus Vesicle-associated membrane protein 1 Proteins 0.000 description 10
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000025743 negative regulation of exocytosis Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 108091005948 blue fluorescent proteins Proteins 0.000 description 9
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 9
- 108010082025 cyan fluorescent protein Proteins 0.000 description 9
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 241000237967 Aplysia Species 0.000 description 8
- 241000252229 Carassius auratus Species 0.000 description 8
- 241000238366 Cephalopoda Species 0.000 description 8
- 241001112695 Clostridiales Species 0.000 description 8
- 108010004469 allophycocyanin Proteins 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 241000257465 Echinoidea Species 0.000 description 7
- 108010048671 Homeodomain Proteins Proteins 0.000 description 7
- 102000009331 Homeodomain Proteins Human genes 0.000 description 7
- 101000652307 Mus musculus Synaptosomal-associated protein 25 Proteins 0.000 description 7
- 210000000172 cytosol Anatomy 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- 108700011848 Drosophila nsyb Proteins 0.000 description 6
- 108010025076 Holoenzymes Proteins 0.000 description 6
- 101000639134 Mus musculus Vesicle-associated membrane protein 2 Proteins 0.000 description 6
- 101000652311 Rattus norvegicus Synaptosomal-associated protein 25 Proteins 0.000 description 6
- 101000639138 Rattus norvegicus Vesicle-associated membrane protein 1 Proteins 0.000 description 6
- 244000062793 Sorghum vulgare Species 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 102000034287 fluorescent proteins Human genes 0.000 description 6
- 108091006047 fluorescent proteins Proteins 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 150000002602 lanthanoids Chemical class 0.000 description 6
- 238000004020 luminiscence type Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 235000019713 millet Nutrition 0.000 description 6
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000006862 quantum yield reaction Methods 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 101000639137 Bos taurus Vesicle-associated membrane protein 2 Proteins 0.000 description 5
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 5
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 101710189801 Synaptosomal-associated protein 25-A Proteins 0.000 description 5
- 206010043376 Tetanus Diseases 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 229910052747 lanthanoid Inorganic materials 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- 108700001009 Drosophila Syb Proteins 0.000 description 4
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 4
- 108091052347 Glucose transporter family Proteins 0.000 description 4
- 101710138657 Neurotoxin Proteins 0.000 description 4
- 101710189545 Synaptosomal-associated protein 23 Proteins 0.000 description 4
- 102100030545 Synaptosomal-associated protein 23 Human genes 0.000 description 4
- 102000013265 Syntaxin 1 Human genes 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000000695 excitation spectrum Methods 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000002504 synaptic vesicle Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- GQMMRLBWXCGBEV-YVMONPNESA-N (nz)-n-[(3-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC([N+]([O-])=O)=C1 GQMMRLBWXCGBEV-YVMONPNESA-N 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 241000252212 Danio rerio Species 0.000 description 3
- 229910052693 Europium Inorganic materials 0.000 description 3
- 101100310544 Gallus gallus SNAP25 gene Proteins 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000545744 Hirudinea Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 229910052771 Terbium Inorganic materials 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 108091005601 modified peptides Proteins 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000000273 spinal nerve root Anatomy 0.000 description 3
- 210000005250 spinal neuron Anatomy 0.000 description 3
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- XJIRSLHMKBUGMR-UHFFFAOYSA-N 1-ethylsulfanylbutane Chemical compound CCCCSCC XJIRSLHMKBUGMR-UHFFFAOYSA-N 0.000 description 2
- BEDDXHFONHIYPB-UHFFFAOYSA-N 2-[methyl-(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]ethyl 2-iodoacetate Chemical compound ICC(=O)OCCN(C)C1=CC=C([N+]([O-])=O)C2=NON=C12 BEDDXHFONHIYPB-UHFFFAOYSA-N 0.000 description 2
- 108010062307 AAVALLPAVLLALLAP Proteins 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 2
- 102000009193 Caveolin Human genes 0.000 description 2
- 108050000084 Caveolin Proteins 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 2
- 229930028154 D-arginine Natural products 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108700009372 Drosophila Snap25 Proteins 0.000 description 2
- 108010012314 Drosophila syntaxin Proteins 0.000 description 2
- 229910052692 Dysprosium Inorganic materials 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101000585070 Homo sapiens Syntaxin-1A Proteins 0.000 description 2
- 101000836154 Homo sapiens Transforming acidic coiled-coil-containing protein 1 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102000008607 Integrin beta3 Human genes 0.000 description 2
- 108010020950 Integrin beta3 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101000652301 Mus musculus Synaptosomal-associated protein 23 Proteins 0.000 description 2
- 101000585067 Mus musculus Syntaxin-1A Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000004874 Synaptophysin Human genes 0.000 description 2
- 108090001076 Synaptophysin Proteins 0.000 description 2
- 108010090618 Syntaxin 1 Proteins 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 102100027049 Transforming acidic coiled-coil-containing protein 1 Human genes 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 210000001943 adrenal medulla Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 210000003737 chromaffin cell Anatomy 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- XHXYXYGSUXANME-UHFFFAOYSA-N eosin 5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 XHXYXYGSUXANME-UHFFFAOYSA-N 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 101150003074 hoxa5 gene Proteins 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 108700024542 myc Genes Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000007900 neurotoxin activity Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 125000006501 nitrophenyl group Chemical group 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 108010043655 penetratin Proteins 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZUDZCQRGSBEBLF-WOUKDFQISA-N (2r,3r,4s,5r)-2-(7,8-dihydroimidazo[2,1-f]purin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN2CCN=C22)=C2N=C1 ZUDZCQRGSBEBLF-WOUKDFQISA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- ZNYQNCQPMDMUAL-UHFFFAOYSA-N 1-[3-(dimethylamino)-4-(2-phenylethenyl)phenyl]pyrrole-2,5-dione Chemical compound CN(C)C1=CC(N2C(C=CC2=O)=O)=CC=C1C=CC1=CC=CC=C1 ZNYQNCQPMDMUAL-UHFFFAOYSA-N 0.000 description 1
- QPYAUURPGVXHFK-UHFFFAOYSA-N 1-[4-(dimethylamino)-3,5-dinitrophenyl]pyrrole-2,5-dione Chemical compound C1=C([N+]([O-])=O)C(N(C)C)=C([N+]([O-])=O)C=C1N1C(=O)C=CC1=O QPYAUURPGVXHFK-UHFFFAOYSA-N 0.000 description 1
- YGIABALXNBVHBX-UHFFFAOYSA-N 1-[4-[7-(diethylamino)-4-methyl-2-oxochromen-3-yl]phenyl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C(C=C1)=CC=C1N1C(=O)C=CC1=O YGIABALXNBVHBX-UHFFFAOYSA-N 0.000 description 1
- RGNHAWFQWRAADF-UHFFFAOYSA-N 1-[4-[[4-(dimethylamino)phenyl]diazenyl]phenyl]pyrrole-2,5-dione Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N2C(C=CC2=O)=O)C=C1 RGNHAWFQWRAADF-UHFFFAOYSA-N 0.000 description 1
- ADEORFBTPGKHRP-UHFFFAOYSA-N 1-[7-(dimethylamino)-4-methyl-2-oxochromen-3-yl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(C)C)=CC=C2C(C)=C1N1C(=O)C=CC1=O ADEORFBTPGKHRP-UHFFFAOYSA-N 0.000 description 1
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QEQAPQHGLVGWMO-UHFFFAOYSA-N 2-hydroxy-4-[(2-iodoacetyl)amino]benzoic acid Chemical compound OC(=O)C1=CC=C(NC(=O)CI)C=C1O QEQAPQHGLVGWMO-UHFFFAOYSA-N 0.000 description 1
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 1
- LJROKJGQSPMTKB-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)-pyridin-2-ylmethyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(O)C=C1 LJROKJGQSPMTKB-UHFFFAOYSA-N 0.000 description 1
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 1
- LSKWDEYBJACPBB-UHFFFAOYSA-N 5-(aziridin-1-ylsulfonyl)-n,n-dimethylnaphthalen-1-amine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N1CC1 LSKWDEYBJACPBB-UHFFFAOYSA-N 0.000 description 1
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 description 1
- APZRMCOINHOQTE-UHFFFAOYSA-N 6-[4-[(2-iodoacetyl)amino]anilino]naphthalene-2-sulfonic acid Chemical compound C1=CC2=CC(S(=O)(=O)O)=CC=C2C=C1NC1=CC=C(NC(=O)CI)C=C1 APZRMCOINHOQTE-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 101000585051 Bos taurus Syntaxin-1A Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 102100028652 Gamma-enolase Human genes 0.000 description 1
- 101710191797 Gamma-enolase Proteins 0.000 description 1
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 101150105462 HIS6 gene Proteins 0.000 description 1
- 101150004541 HOXC8 gene Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000585079 Homo sapiens Syntaxin-1B Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 101100018264 Mus musculus Hoxb4 gene Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 108010049175 N-substituted Glycines Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 101100395023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-7 gene Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010005730 R-SNARE Proteins Proteins 0.000 description 1
- 101000585073 Rattus norvegicus Syntaxin-1A Proteins 0.000 description 1
- 101000642674 Rattus norvegicus Syntaxin-2 Proteins 0.000 description 1
- 101000642686 Rattus norvegicus Syntaxin-3 Proteins 0.000 description 1
- 102000000583 SNARE Proteins Human genes 0.000 description 1
- 108010041948 SNARE Proteins Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000002215 Synaptobrevin Human genes 0.000 description 1
- 108030001722 Tentoxilysin Proteins 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010017749 Vesicle-Associated Membrane Protein 3 Proteins 0.000 description 1
- 102000004604 Vesicle-Associated Membrane Protein 3 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HOUJZQLNVOLPOY-FCDQGJHFSA-N [(e)-(3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-ylidene)amino]thiourea Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11O/C(=N/NC(=S)N)C2=CC=CC=C21 HOUJZQLNVOLPOY-FCDQGJHFSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- UIZLQMLDSWKZGC-UHFFFAOYSA-N cadmium helium Chemical compound [He].[Cd] UIZLQMLDSWKZGC-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- KPBGWWXVWRSIAY-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-6-isothiocyanato-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=C(N=C=S)C=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 KPBGWWXVWRSIAY-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108700005856 engrailed 2 Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
- 229950009774 gramicidin s Drugs 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000053957 human STX1A Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- XJENLUNLXRJLEZ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=C(C)C(N(CC)CC)=CC2=[O+]C=2C=C(N(CC)CC)C(C)=CC=2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XJENLUNLXRJLEZ-UHFFFAOYSA-M 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 108010087493 microtubule-associated protein acetyltransferase Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- UATCLPJEZJKNHE-UHFFFAOYSA-N n-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)-2-iodoacetamide Chemical compound O1C(=O)C2=CC(NC(=O)CI)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 UATCLPJEZJKNHE-UHFFFAOYSA-N 0.000 description 1
- GSJAHPSIMGWTCS-UHFFFAOYSA-N n-cyclohexyl-n'-pyren-1-ylmethanediimine Chemical compound C1CCCCC1N=C=NC1=CC=C(C=C2)C3=C4C2=CC=CC4=CC=C13 GSJAHPSIMGWTCS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000037418 vocal dysfunction Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
Abstract
Description
本発明は、一般的には蛍光共鳴エネルギー転移およびプロテアーゼアッセイに関し、より具体的には、クロストリジウム毒素活性を細胞ベースでアッセイする方法に関する。
破傷風、およびまれではあるが致死的な疾患となる可能性のあるボツリヌス中毒症の神経麻痺症候群は、クロストリジウム属の細菌によって産生される神経毒素により引き起こされる。これらのクロストリジウム神経毒素は、神経細胞に対し非常に強くまた特異的な毒であり、ボツリヌス毒素のヒト致死量はナノグラムのオーダーである。従って、食料品中に存在するボツリヌス毒素が微量であっても公衆衛生を害し、それは厳しい試験を通して回避されなければならない。
本発明は、送達薬剤およびクロストリジウム毒素基質を含む組成物を提供し、このクロストリジウム毒素基質は、ドナー・フルオロフォア;ドナー・フルオロフォアの発光スペクトルと重なる吸収スペクトルを有するアクセプター;および切断部位がドナー・フルオロフォアとアクセプターの間にあり、適切な条件下、共鳴エネルギー転移がドナー・フルオロフォアとアクセプターの間で見られるクロストリジウム毒素認識配列を含む。本発明の基質組成物において、送達薬剤は、例えばクロストリジウム毒素基質に共有結合されていてもよく、さらに、例えば、タンパク質、ペプチドまたはペプチド模倣物であっても良い。ある態様においては、基質組成物は、送達薬剤がクロストリジウム毒素基質と動作可能に縮合しているキメラタンパク質、ペプチドまたはペプチド模倣物である。このようなキメラ基質組成物は、例えば、最大50または100残基長のペプチドまたはペプチド模倣物であり得る。
本発明は、試料中の活性クロストリジウム毒素の有無を測定するため、または全ての血清型のボツリヌス毒素および破傷風毒素を含むいずれかのクロストリジウム毒素の活性を測定するための、インビボおよびインビトロでの細胞ベースのアッセイを提供する。本発明の新規な基質組成物、細胞およびアッセイにより、動物毒性研究に対する必要性が減少し、さらになお、複数の毒性機能、すなわち、毒素の結合および細胞内取込、細胞質サイトゾルへのトランスロケーションおよびプロテアーゼ活性を分析するために役立つ。これらの新規な組成物および方法は、未精製かつ大量の試料ならびに高度に精製されている二本鎖毒素(dichain toxins)または製剤化した毒素製品を分析するために使用することができ、さらに自動化ハイスループットアッセイフォーマットに適用しやすい。
E=1−FDA/FD=1/(1+(R/R0)6)
(式中、FDAおよびFDは、それぞれ、アクセプターの存在または非存在下のドナー・フルオロフォアの蛍光強度であり、Rはドナー・フルオロフォアとアクセプターの間の距離である)。
Foerster半径(R0)は、共鳴エネルギー転移が50%有効、すなわち、励起ドナー・フルオロフォアの50%がFRETによって不活性化される距離である。Foerster半径の大きさは、ドナー・フルオロフォアの量子収率;アクセプターの消光係数;および、ドナー・フルオロフォアの発光スペクトルとアクセプターの励起スペクトルの間の重複に依存する。
RO=[8.8×1023・κ2・n−4・QYD・J(λ)]1/6 Å
(式中、
κ2=双極子配向因子(dipole orientation factor)(レンジ0から4;κ2=2/3、ランダムに配向したドナーおよびアクセプターについて)、
QYD=アクセプター非存在下におけるドナーの蛍光量子収率、
n=屈折率、
J(λ)=スペクトル重複積分(spectral overlap integral)
=∫εA(λ)・FD(λ)・λ4dλ cm3M−1
(式中、εA=アクセプターの励起係数、
FD=全積分強度のフラクションとしてのドナー蛍光発光強度である)、
である(Foerster, Ann. Physik 2:55 75 (1948))。
BPE, B−フィコエリトリン;
CF, カルボキシフルオレセインスクシンイミジルエステル;
CPM, 7−ジエチルアミノ−3−(4'−マレイミジルフェニル)−4−メチルクマリン;
CY5, カルボキシメチルインドシアニン−N−ヒドロキシスクシンイミジルエステル;
diI−C18, 1,1'−ジオクタデシル−3−3,3,3',3'−テトラメチル−インドカルボシアニン;
diO−C14, 3,3'−ジテトラデシルオキサカルボシアニン;
DABM, 4−ジメチルアミノフェニルアゾ−フェニル−4'−マレイミド;
DACM, (7−(ジメチルアミノ)クマリン−4−イル)−アセチル;
DANZ, ダンシルアジリジン(dansylaziridine);
DDPM, N−(4−ジメチルアミノ−3,5−ジニトロフェニル)マレイミド;
DMAMS, ジメチルアミノ−4−マレイミドスチルベン(maleimidostilbene);
DSMN, N−(2,5'−ジメトキシスチベン(dimethoxystiben)−4−イル)−マレイミド;
DNP, 2,4−ジニトロフェニル;
ε−A, 1,N6−エタノアデノシン;
EIA, 5−ヨードアセテトアミド(iodoacetetamido)エオシン;
EITC, エオシン−5−イソチオシアネート;
ENAI, エオシン N−アセチルイミダゾール;
EM, エオシンマレイミド;
ErITC, エリスロシン−5'-イソチオシアネート;
ETSC, エオシン チオセミカラジド(thiosemicarazide);
F2DNB, 1,5−ジフルオロ(difluro)−2,4'−ジニトロベンゼン;
F2DPS, 4,4'−ジフルオロ−3,3'−ジニトロフェニルスルホン;
FITC, フルオレセインチオセミカルバジド;
IAANS, 2−(4'−ヨードアセトアミド)アニリーノ)ナフタレン−6−スルホン酸;
IAEDANS, 5−(2−((ヨードアセチル)アミノ)エチル)アミノ)−ナフタレン−1−スルホン酸;
IAF, 5−ヨードアセトアミドフルオレセイン;
IANBD, N−((2−(ヨードアセトキシ)エチル)−N−メチル)アミノ−7−ニトロベンズ−2−オキサ−1,3−ジアゾール;
IPM, 3(4−イソチオシアネートフェニル)7−ジエチル−4−アミノ−4−メチルクマリン;
ISA, 4−(ヨードアセトアミド)サリチル酸;
LRH, リスアミンローダミン(lissaminerhodamine);
LY, ルシファーイエロー;
mBBR, モノブロモビアマン(monobromobiamane);
MNA, (2−メトキシ−1−ナフチル)−メチル;
NAA, 2−ナフトキシ酢酸;
NBD, 7−ニトロ−2,1,3−ベンズオキサジアゾール(benzoxadiazol)−4−イル;
NCP, N−シクロヘキシル−N'−(1−ピレニル)カルボジイミド;
ODR, オクタデシルローダミン;
PM, N−(1−ピレン)−マレイミド;
SRH, スルホローダミン;
TMR, テトラメチルローダミン;
TNP, トリニトロフェニル; および
TR, テキサスレッド。
Claims (82)
- 送達薬剤ならびに
(a)ドナー・フルオロフォア;
(b)該ドナー・フルオロフォアの発光スペクトルと重なる吸収スペクトルを有するアクセプター;および、
(c)切断部位を含むクロストリジウム毒素認識配列、
を含み、該切断部位が該ドナー・フルオロフォアと該アクセプターの間にあり、適切な条件下、該ドナー・フルオロフォアと該アクセプターの間で共鳴エネルギー転移が示されるクロストリジウム毒素基質を含有する薬剤。 - 送達薬剤がクロストリジウム毒素基質に共有結合している、請求項1記載の基質。
- 送達薬剤がタンパク質、ペプチドまたはペプチド模倣物である、請求項2に記載の基質組成物。
- 送達薬剤を含むキメラタンパク質、ペプチドまたはペプチド模倣物がクロストリジウム毒素基質に動作可能に縮合している、請求項3に記載の基質組成物。
- 送達薬剤がアンテナペディアタンパク質またはその活性フラグメントである、請求項3に記載の基質組成物。
- アンテナペディアタンパク質またはその活性フラグメントがアミノ酸配列RQIKIWFQNRRMKWKK(配列番号1)を有する、請求項5に記載の基質組成物。
- 送達薬剤がHIV TATタンパク質またはその活性フラグメントである、請求項3に記載の基質組成物。
- HIV TATタンパク質またはその活性フラグメントがアミノ酸配列YGRKKRRQRRR(配列番号2)を有する、請求項7に記載の基質組成物。
- 送達薬剤が単純ヘルペスウィルスV22タンパク質またはその活性フラグメントである、請求項3に記載の基質組成物。
- 単純ヘルペスウィルスV22タンパク質が配列番号3のアミノ酸配列を有する、請求項9に記載の基質組成物。
- 送達薬剤がクロストリジウム毒素基質と非共有結合している、請求項1に記載の基質組成物。
- 送達薬剤がChariotTMおよびMPGペプチドからなる群から選択される、請求項11に記載の基質組成物。
- ボツリヌス毒素認識配列を含むボツリヌス毒素基質を含有する、請求項11に記載の基質組成物。
- BoNT/A認識配列を含むBoNT/A基質を含有する、請求項13に記載の基質組成物。
- Gln-Argを含むSNAP-25の少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/A基質が含む、請求項14記載の基質組成物。
- BoNT/B認識配列を有するBoNT/B基質を含有する、請求項13に記載の基質組成物。
- Gln-Pheを含むVAMPの少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/B基質が含む、請求項16記載の基質組成物。
- BoNT/C1認識配列を有するBoNT/C1基質を含有する、請求項13に記載の基質組成物。
- Lys-Alaを含むシンタキシンの少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/C1基質が含む、請求項18に記載の基質組成物。
- Arg-Alaを含むSNAP-25の少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/C1基質が含む、請求項18に記載の基質組成物。
- BoNT/D基質がBoNT/D認識配列を含む、請求項13に記載の基質組成物。
- Lys-Leuを含むVAMPの少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/D基質が含む、請求項21に記載の基質組成物。
- BoNT/E基質がBoNT/E認識配列を含む、請求項13に記載の基質組成物。
- Arg-Ileを含むSNAP-25の少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/E基質が含む、請求項23に記載の基質組成物。
- BoNT/F基質がBoNT/F認識配列を含む、請求項13に記載の基質組成物。
- Gln-Lysを含むVAMPの少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/F基質が含む、請求項25に記載の基質組成物。
- BoNT/G基質がBoNT/G認識配列を含む、請求項13に記載の基質組成物。
- Ala-Alaを含むVAMPの少なくとも6つの連続残基またはそのペプチド模倣物をBoNT/G基質が含む、請求項27に記載の基質組成物。
- TeNT基質がTeNT認識配列を含む、請求項1に記載の基質組成物。
- Gln-Pheを含むVAMPの少なくとも6つの連続残基またはそのペプチド模倣物をTeNT基質が含む、請求項29に記載の基質組成物。
- ドナー・フルオロフォアがフルオレセイン、Alexa Fluor(登録商標)488、DBCYLおよびBODIPYからなる群から選択される、請求項1に記載の基質組成物。
- アクセプターがアクセプター・フルオロフォアである、請求項1に記載の基質組成物。
- アセクセプター・フルオロフォアが少なくとも1マイクロ秒の蛍光寿命を有する、請求項23に記載の基質組成物。
- アクセプターがテトラメチルローダミン、EDANSおよびQSY(登録商標)7からなる群から選択される、請求項1に記載の基質組成物。
- アクセプターが非蛍光である、請求項1に記載の基質組成物。
- ペプチドまたはペプチド模倣物が最大100残基を有する、請求項4に記載の基質組成物。
- ペプチドまたはペプチド模倣物が最大50残基を有する、請求項4に記載の基質組成物。
- (a)ドナー・フルオロフォア;
(b)該ドナー・フルオロフォアの発光スペクトルと重なる吸収スペクトルを有するアクセプター;および、
(c)切断部位を含むクロストリジウム毒素認識配列、
を含み、該切断部位が該ドナー・フルオロフォアと該アクセプターの間にあり、適切な条件下、該ドナー・フルオロフォアと該アクセプターの間で共鳴エネルギー転移が見られるクロストリジウム毒素基質を有する細胞。 - トランスフェクト細胞である、請求項38に記載の細胞。
- 安定なトラスフェクト細胞である、請求項38に記載の細胞。
- 初代培養細胞である、請求項38に記載の細胞。
- 株化細胞である、請求項38に記載の細胞。
- ヒト細胞である、請求項38に記載の細胞。
- ニューロンである、請求項38〜41のいずれか1項に記載の細胞。
- 中枢神経系(CNS)ニューロンである、請求項38に記載の細胞。
- 末梢ニューロンである、請求項38に記載の細胞。
- 神経芽細胞腫、脊髄ニューロン、後根神経節ニューロン、大脳皮質ニューロン、小脳ニューロン、海馬ニューロンおよび運動ニューロンからなる群から選択される、請求項39または40に記載の細胞。
- 神経芽腫細胞である、請求項45に記載の細胞。
- 非神経細胞である、請求項38に記載の細胞。
- 膵腺房細胞である、請求項47に記載の細胞。
- (a)ドナー・フルオロフォア;
(b)該ドナー・フルオロフォアの発光スペクトルと重なる吸収スペクトルを有するアクセプター;および、
(c)切断部位を含むクロストリジウム毒素認識配列、
を含み、該切断部位が該ドナー・フルオロフォアと該アクセプターの間にあり、適切な条件下、該ドナー・フルオロフォアと該アクセプターの間で共鳴エネルギー転移が見られるクロストリジウム毒素基質をコードする核酸分子を含む、細胞。 - 該核酸分子が安定にトランスフェクトされている、請求項51に記載の細胞。
- ヒト細胞である、請求項51に記載の細胞。
- 神経細胞である、請求項51に記載の細胞。
- 非神経細胞である、請求項51に記載の細胞。
- 核酸分子が構成性調節エレメントに連結されている、請求項51記載の細胞。
- 核酸分子が誘導性調節エレメントに連結されている、請求項51記載の細胞。
- 誘導性プロモーターがテトラサイクリン調節型調節エレメントである、請求項57に記載の細胞。
- 誘導性プロモーターがエクジソン誘導性調節エレメントである、請求項57に記載の細胞。
- クロストリジウム毒素基質が緑色蛍光タンパク質(GFP)を含む、請求項51、52、56または57に記載の細胞。
- クロストリジウム毒素活性を測定する方法であって、
(a)(i) ドナー・フルオロフォア;
(ii) 該ドナー・フルオロフォアの発光スペクトルと重なる吸収スペクトルを有するアクセプター;および、
(iii) 該ドナー・フルオロフォアと該アクセプターの間にある切断部位を含むクロストリジウム毒素認識配列、
を含み、適切な条件下、該ドナー・フルオロフォアと該アクセプターの間で共鳴エネルギー転移が見られるクロストリジウム毒素基質を有する細胞を、試料と接触させること、
(b)該ドナー・フルオロフォアを励起すること、および
(c) 該接触させた細胞の共鳴エネルギー転移をコントロール細胞と比較して測定することを含み、
該コントロール細胞と比較した場合の該接触細胞の共鳴エネルギー転移における差異がクロストリジウム毒素活性を示す方法。 - 該クロストリジウム毒素基質がボツリヌス毒素基質である、請求項61に記載の方法。
- 該ボツリヌス毒素基質がBoNT/A認識配列を含むBoNT/A基質である、請求項62に記載の方法。
- 該ボツリヌス毒素基質がBoNT/B認識配列を含むBoNT/B基質である、請求項62に記載の方法。
- 該ボツリヌス毒素基質がBoNT/C1認識配列を含むBoNT/C1基質である、請求項62に記載の方法。
- 該ボツリヌス毒素基質がBoNT/D認識配列を含むBoNT/D基質である、請求項62に記載の方法。
- 該ボツリヌス毒素基質がBoNT/E認識配列を含むBoNT/E基質である、請求項62に記載の方法。
- 該ボツリヌス毒素基質がBoNT/F認識配列を含むBoNT/F基質である、請求項62に記載の方法。
- 該ボツリヌス毒素基質がBoNT/G認識配列を含むBoNT/G基質である、請求項62に記載の方法。
- 該クロストリジウム毒素基質がTeNT認識配列を含むTeNT毒素基質である、請求項61に記載の方法。
- 該試料が未精製の細胞溶解物である、請求項61に記載の方法。
- 該試料が単離したクロストリジウム毒素である、請求項61に記載の方法。
- 該試料が製剤化クロストリジウム毒素製品である、請求項61に記載の方法。
- 該試料がBOTOX(登録商標)である、請求項61に記載の方法。
- 該試料が食品である、請求項61に記載の方法。
- 段階(c)が該接触細胞のドナー蛍光強度を検出することを含み、該コントロール細胞と比較した該接触細胞のドナー蛍光強度の増加がクロストリジウム毒素活性を示す、請求項61に記載の方法。
- 段階(c)が該接触細胞のアクセプター蛍光強度を検出することを含み、該コントロール細胞と比較した該接触細胞のアクセプター蛍光強度の減少がクロストリジウム毒素活性を示す、請求項61に記載の方法。
- 段階(c)が該接触細胞のアクセプター発光極大およびドナー・フルオロフォア発光極大を検出することを含み、該アクセプター発光極大付近から該ドナー・フルオロフォア発光極大付近への発光極大のシフトがクロストリジウム毒素活性を示す、請求項61記載の方法。
- 段階(c)がアクセプター発光極大付近の蛍光振幅のドナー・フルオロフォア発光極大付近の蛍光振幅に対する比を検出することを含み、コントロール細胞と比較した該接触細胞の比の減少がクロストリジウム毒素活性を示す、請求項61に記載の方法。
- 段階(c)が該接触細胞におけるドナー・フルオロフォアの励起状態寿命を検出することを含み、コントロール細胞と比較した該接触細胞のドナー・フルオロフォア励起状態寿命の増加がクロストリジウム毒素活性を示す、請求項61に記載の方法。
- 段階(c)を時間間隔の後に1回以上反復することをさらに含む、請求項61に記載の方法。
- 該クロストリジウム毒素活性に適した条件を選択して、アッセイが線形であるようにする、請求項61に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/261,161 US7183066B2 (en) | 2002-09-27 | 2002-09-27 | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
PCT/US2003/028092 WO2004029576A2 (en) | 2002-09-27 | 2003-09-04 | Cell-based fluorescence resonance energy transfer (fret) assays for clostridial toxins |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006502378A true JP2006502378A (ja) | 2006-01-19 |
JP2006502378A5 JP2006502378A5 (ja) | 2006-10-12 |
JP4554369B2 JP4554369B2 (ja) | 2010-09-29 |
Family
ID=32041812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004540055A Expired - Fee Related JP4554369B2 (ja) | 2002-09-27 | 2003-09-04 | クロストリジウム毒素に関する細胞ベースの蛍光共鳴エネルギー転移(fret)アッセイ |
Country Status (17)
Country | Link |
---|---|
US (3) | US7183066B2 (ja) |
EP (1) | EP1543329B1 (ja) |
JP (1) | JP4554369B2 (ja) |
KR (1) | KR20050071506A (ja) |
CN (1) | CN1296712C (ja) |
AU (2) | AU2003282790B2 (ja) |
BR (1) | BR0314795A (ja) |
CA (1) | CA2500040C (ja) |
CO (1) | CO5721032A2 (ja) |
DK (1) | DK1543329T3 (ja) |
IL (1) | IL167410A (ja) |
MX (1) | MXPA05003128A (ja) |
NO (1) | NO20051049L (ja) |
PL (1) | PL376103A1 (ja) |
RU (1) | RU2005109385A (ja) |
WO (1) | WO2004029576A2 (ja) |
ZA (1) | ZA200501500B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008220302A (ja) * | 2007-03-14 | 2008-09-25 | Hiroshima Univ | タンパク質蓄積による神経変性疾患治療薬物のスクリーニング系 |
JP2010539477A (ja) * | 2007-09-14 | 2010-12-16 | バイオセンテイネル・エル・エル・シー | 切断配列とスペーサーを用いた共鳴エネルギー転移アッセイ |
JP2015534076A (ja) * | 2012-10-23 | 2015-11-26 | イプセン バイオイノベーション リミテッド | エンドソーム輸送評価試験法 |
JP2022512565A (ja) * | 2018-09-28 | 2022-02-07 | イプセン バイオファーム リミテッド | 細胞ベースのクロストリジウム神経毒アッセイ |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080038274A1 (en) * | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
US7354735B2 (en) * | 2001-05-24 | 2008-04-08 | Hong Kong University Of Science And Technology | Nucleic acid encoding fluorescent protein constructs and methods for detecting apoptosis |
US7332567B2 (en) * | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
US20080064054A1 (en) * | 2001-08-28 | 2008-03-13 | Ester Fernandez-Salas | Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity |
US7208285B2 (en) * | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
US8022172B2 (en) * | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
US20060063221A1 (en) * | 2004-09-21 | 2006-03-23 | Williams Dudley J | Lanthanide-based substrates and methods for determining clostridial toxin activity |
US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
US7183066B2 (en) * | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
AU2003272800A1 (en) * | 2002-10-01 | 2004-04-23 | University Of Maryland | Methods for identifying inhibitors of botulinum neurotoxins |
WO2005076785A2 (en) * | 2003-12-19 | 2005-08-25 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
JP4970057B2 (ja) * | 2004-02-24 | 2012-07-04 | アラーガン、インコーポレイテッド | ボツリヌス毒素スクリーニングアッセイ |
US8497081B2 (en) * | 2004-02-24 | 2013-07-30 | Allergan, Inc. | Botulinum toxin screening assays |
EP1784420B1 (en) * | 2004-09-01 | 2008-12-03 | Allergan, Inc. | Degradable clostridial toxins |
US8617838B2 (en) * | 2004-09-20 | 2013-12-31 | University Of Massachusetts | Fluorescent proteins and related methods and compounds |
US7399607B2 (en) * | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
US8031338B2 (en) * | 2004-12-02 | 2011-10-04 | Vanderbilt University | Measuring Forster resonance energy transfer with polarized and depolarized light |
CA2605160A1 (en) | 2005-04-05 | 2006-10-05 | Allergan, Inc. | Clostridial toxin activity assays |
WO2006107921A2 (en) * | 2005-04-05 | 2006-10-12 | Allergan, Inc. | Lipophilic dye-based fret assays for clostridial toxin activity |
DE102005020384A1 (de) * | 2005-05-02 | 2006-11-09 | Therainvention Gmbh | Spektroskopisches Verfahren zum Nachweis von Analyten |
DK1926744T4 (en) * | 2005-09-19 | 2019-01-28 | Allergan Inc | CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES |
ATE555387T1 (de) * | 2005-10-12 | 2012-05-15 | Allergan Inc | Tests der molekularen oder subzellulären nähe unter verwendung von depolarisierung nach resonanzenergietransfer (daret) |
FR2903495A1 (fr) * | 2006-07-06 | 2008-01-11 | Pharmaleads Soc Par Actions Si | PROCEDE DE DETECTION D'INTERACTIONS A L'AIDE DU RAPPORTEUR DE FLUORESCENCE Pya |
US7733470B2 (en) * | 2007-06-26 | 2010-06-08 | Photon Technology International, Inc. | Method and apparatus for real-time measurement and calculation of a fluorescent lifetime |
KR101604515B1 (ko) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 a 활성 검정 |
SG2014009112A (en) | 2008-03-14 | 2014-04-28 | Allergan Inc | Immuno-based botulinum toxin serotype a activity assays |
CN105833254A (zh) | 2008-12-10 | 2016-08-10 | 阿勒根公司 | 梭菌毒素药物组合物 |
US8492109B2 (en) * | 2009-01-20 | 2013-07-23 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
RU2543650C2 (ru) | 2009-03-13 | 2015-03-10 | Аллерган, Инк. | Иммунологические тесты на активность эндопептидаз с измененной нацеленностью |
JP5717657B2 (ja) | 2009-03-13 | 2015-05-13 | アラーガン、インコーポレイテッドAllergan,Incorporated | 免疫系ボツリヌス毒素血清型a活性アッセイに有用な細胞 |
US9247611B2 (en) * | 2009-06-01 | 2016-01-26 | Apple Inc. | Light source with light sensor |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
WO2011039953A1 (ja) * | 2009-09-29 | 2011-04-07 | 三井造船株式会社 | Fret測定方法及び装置 |
WO2011041779A1 (en) | 2009-10-02 | 2011-04-07 | Allergan, Inc. | In vitro method of determining changes in a protein environment |
FR2958293B1 (fr) | 2010-04-01 | 2014-09-26 | Centre Nat Rech Scient | Outils pour l'identification de ligands de lingo-1,lingo-2, lingo-3 et lingo-4, et utilisations |
CN102243176B (zh) * | 2010-05-14 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种体外分子水平荧光法排除筛选药物假阳性结果的方法 |
CA2801421A1 (en) * | 2010-06-11 | 2012-04-12 | Synaptic Research, Llc | N-end rule protease activity indication methods and uses thereof |
CN103228669B (zh) * | 2010-09-27 | 2016-02-24 | 国立大学法人京都大学 | 基于荧光共振能量转移的原理的单分子型fret生物传感器接头 |
US8569254B2 (en) | 2010-12-10 | 2013-10-29 | National Yang Ming University | Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same |
US11325954B2 (en) | 2011-06-01 | 2022-05-10 | Biomadison, Inc. | Compositions and methods for stability testing of botulinum toxin |
US9303285B2 (en) | 2012-01-04 | 2016-04-05 | Biomadison, Inc. | Methods and compounds for increasing sensitivity of botulinum assays |
CN107475293A (zh) * | 2011-06-01 | 2017-12-15 | 拜奥麦迪逊公司 | 非‑fret肉毒梭菌测定法 |
US10908146B2 (en) | 2011-06-01 | 2021-02-02 | Biomadison, Inc. | Compositions and methods for improving sensitivity in cell based assays |
US10451621B2 (en) | 2011-12-31 | 2019-10-22 | Allergan, Inc. | Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A |
WO2013103983A1 (en) * | 2012-01-06 | 2013-07-11 | The Research Foundation Of State University Of New York | High throughput screening of live cells |
EP3030905B9 (en) * | 2013-08-09 | 2024-04-03 | Biomadison, Inc. | Botulinum toxin assay with improved sensitivity |
EP3404112B1 (en) | 2013-10-25 | 2020-08-26 | BioMadison, Inc. | Enzyme assay with duplicate fluorophores |
US10527620B2 (en) | 2014-07-07 | 2020-01-07 | Allergan, Inc. | Method of detecting cleaved SNAP25 in tissue samples |
KR20170073588A (ko) * | 2014-08-12 | 2017-06-28 | 바이오메디슨, 인코퍼레이티드 | 변형된 경쇄 특이성을 갖는 보툴리눔 신경독 및 이를 생성하기 위한 방법 |
CN104359883A (zh) * | 2014-11-13 | 2015-02-18 | 贵阳医学院 | 人源沉默信息调节因子6的活性荧光检测方法 |
ES2788999T3 (es) | 2014-12-23 | 2020-10-23 | Merz Pharma Gmbh & Co Kgaa | Envase prellenado de toxina botulínica |
CN105784656B (zh) * | 2016-03-16 | 2019-01-01 | 大连理工大学 | 一种检测活细胞内RhoGDIα蛋白活性的生物探针 |
TWI737742B (zh) | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用 |
CN109803672A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 稳定的非蛋白质梭菌毒素组合物 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN108305912B (zh) * | 2017-01-11 | 2024-03-26 | 中国科学院上海微系统与信息技术研究所 | 具有波长选择性的石墨烯仿生光探测器及其制备方法 |
BR112019025394A2 (pt) * | 2017-06-07 | 2020-06-30 | Original G B.V. | método para detectar um micróbio de deterioração de alimentos e kit para a detecção de microrganismos de deterioração de alimentos |
EP3762489B1 (en) * | 2018-03-09 | 2023-07-19 | Sartorius BioAnalytical Instruments, Inc. | Methods and compositions for live cell analysis of intracellular atp |
CN108333342A (zh) * | 2018-05-14 | 2018-07-27 | 广东药科大学 | 一种快速检测牛奶中四环素类药物残留的方法 |
CN109211863B (zh) * | 2018-10-26 | 2021-04-20 | 大连民族大学 | 利用Eu2+f-f跃迁光谱检测爆炸物TNP的方法 |
AR119109A1 (es) * | 2019-06-07 | 2021-11-24 | Synaptic Res Llc | Células genéticamente manipuladas |
US20210373021A1 (en) * | 2020-06-01 | 2021-12-02 | Galderma Holding S.A. | Snap-25 reporter constructs and methods of using the same |
CN112557353B (zh) * | 2020-12-17 | 2022-02-18 | 天津工业大学 | 一种基于延迟发光光谱的细胞活力检测方法和装置 |
WO2024107023A1 (ko) * | 2022-11-18 | 2024-05-23 | 주식회사 바이오링크스 | 재조합 형광단백질을 이용한 세포 기반 보툴리눔 독소의 검출 또는 활성 측정 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05505102A (ja) * | 1989-12-21 | 1993-08-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 真核細胞の中に分子を配達する方法 |
JPH10504801A (ja) * | 1994-06-03 | 1998-05-12 | マイクロバイオロジカル リサーチ オーソリティー | 毒素アッセイ |
WO2001092312A1 (fr) * | 2000-06-02 | 2001-12-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | SUBSTRAT PEPTIDIQUE RECONNU PAR LA TOXINE BOTULIQUE DE TYPE BoNT/B ET SON UTILISATION POUR DOSER ET/OU DETECTER LADITE TOXINE OU DES INHIBITEURS CORRESPONDANTS |
WO2002042732A2 (en) * | 2000-11-22 | 2002-05-30 | The Regents Of The University Of California | A method to measure the activation state of signaling pathways in cells |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5962637A (en) * | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US6069010A (en) | 1995-09-11 | 2000-05-30 | Axys Pharmaceuticals, Inc. | High throughput gene inactivation with large scale gene targeting |
US6803188B1 (en) * | 1996-01-31 | 2004-10-12 | The Regents Of The University Of California | Tandem fluorescent protein constructs |
US5965699A (en) * | 1996-11-06 | 1999-10-12 | The United States Of America As Represented By The Secretary Of The Army | Assay for the proteolytic activity of serotype a from clostridium botulinum |
JP2002505077A (ja) | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
EP1073763A4 (en) | 1998-04-28 | 2002-08-07 | Univ Washington | METHODS FOR TRANSDUCING FUSION MOLECULES |
US7090976B2 (en) * | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
DE69903337T2 (de) | 1998-10-30 | 2003-08-21 | Cellomics, Inc. | Ein screeningsystem auf zellbasis |
AU2172800A (en) | 1998-12-10 | 2000-06-26 | Washington University | Protein transduction system and methods of use thereof |
DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
CA2398583A1 (en) | 2000-02-11 | 2001-08-16 | Cellomics, Inc. | Peptide biosensors for anthrax protease |
US6325899B1 (en) | 2000-03-10 | 2001-12-04 | Action Caps, Llc | Disposable and recyclable intermediates for use in electrostatic coating processes |
DE60131468D1 (de) * | 2000-09-25 | 2007-12-27 | U S Medical Res Inst Of Infect | Hoch-durchsatz assays für proteolytische aktivitäten von clostridium neurotoxinen |
AU4755502A (en) * | 2001-06-14 | 2002-12-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cofactor-based screening method for nuclear receptor modulators and related modulators |
US8022172B2 (en) | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
US20080064054A1 (en) | 2001-08-28 | 2008-03-13 | Ester Fernandez-Salas | Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity |
US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
US7208285B2 (en) | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
US7183066B2 (en) | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
JP4970057B2 (ja) | 2004-02-24 | 2012-07-04 | アラーガン、インコーポレイテッド | ボツリヌス毒素スクリーニングアッセイ |
US7399607B2 (en) | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
WO2006107921A2 (en) | 2005-04-05 | 2006-10-12 | Allergan, Inc. | Lipophilic dye-based fret assays for clostridial toxin activity |
ATE555387T1 (de) | 2005-10-12 | 2012-05-15 | Allergan Inc | Tests der molekularen oder subzellulären nähe unter verwendung von depolarisierung nach resonanzenergietransfer (daret) |
-
2002
- 2002-09-27 US US10/261,161 patent/US7183066B2/en not_active Expired - Lifetime
-
2003
- 2003-09-04 KR KR1020057005144A patent/KR20050071506A/ko not_active Application Discontinuation
- 2003-09-04 CA CA2500040A patent/CA2500040C/en not_active Expired - Lifetime
- 2003-09-04 RU RU2005109385/15A patent/RU2005109385A/ru not_active Application Discontinuation
- 2003-09-04 AU AU2003282790A patent/AU2003282790B2/en not_active Expired
- 2003-09-04 CN CNB038228629A patent/CN1296712C/zh not_active Expired - Lifetime
- 2003-09-04 PL PL03376103A patent/PL376103A1/xx not_active Application Discontinuation
- 2003-09-04 WO PCT/US2003/028092 patent/WO2004029576A2/en active Application Filing
- 2003-09-04 JP JP2004540055A patent/JP4554369B2/ja not_active Expired - Fee Related
- 2003-09-04 EP EP03774466.1A patent/EP1543329B1/en not_active Revoked
- 2003-09-04 BR BR0314795-9A patent/BR0314795A/pt not_active Application Discontinuation
- 2003-09-04 MX MXPA05003128A patent/MXPA05003128A/es unknown
- 2003-09-04 DK DK03774466.1T patent/DK1543329T3/en active
-
2005
- 2005-02-21 ZA ZA2005/01500A patent/ZA200501500B/en unknown
- 2005-02-25 NO NO20051049A patent/NO20051049L/no unknown
- 2005-03-13 IL IL167410A patent/IL167410A/en active IP Right Grant
- 2005-03-23 CO CO05026476A patent/CO5721032A2/es not_active Application Discontinuation
-
2007
- 2007-01-09 US US11/621,212 patent/US20070122858A1/en not_active Abandoned
-
2008
- 2008-08-15 US US12/192,925 patent/US7749759B2/en not_active Expired - Fee Related
-
2009
- 2009-10-02 AU AU2009222589A patent/AU2009222589B2/en not_active Expired
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05505102A (ja) * | 1989-12-21 | 1993-08-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 真核細胞の中に分子を配達する方法 |
JPH10504801A (ja) * | 1994-06-03 | 1998-05-12 | マイクロバイオロジカル リサーチ オーソリティー | 毒素アッセイ |
WO2001092312A1 (fr) * | 2000-06-02 | 2001-12-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | SUBSTRAT PEPTIDIQUE RECONNU PAR LA TOXINE BOTULIQUE DE TYPE BoNT/B ET SON UTILISATION POUR DOSER ET/OU DETECTER LADITE TOXINE OU DES INHIBITEURS CORRESPONDANTS |
WO2002042732A2 (en) * | 2000-11-22 | 2002-05-30 | The Regents Of The University Of California | A method to measure the activation state of signaling pathways in cells |
Non-Patent Citations (1)
Title |
---|
JPN6008039049, ANNE,C. et al, "High−throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity", Anal Biochem, 2001, Vol.291, No.2, p.253−61 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008220302A (ja) * | 2007-03-14 | 2008-09-25 | Hiroshima Univ | タンパク質蓄積による神経変性疾患治療薬物のスクリーニング系 |
JP2010539477A (ja) * | 2007-09-14 | 2010-12-16 | バイオセンテイネル・エル・エル・シー | 切断配列とスペーサーを用いた共鳴エネルギー転移アッセイ |
JP2015534076A (ja) * | 2012-10-23 | 2015-11-26 | イプセン バイオイノベーション リミテッド | エンドソーム輸送評価試験法 |
JP2022512565A (ja) * | 2018-09-28 | 2022-02-07 | イプセン バイオファーム リミテッド | 細胞ベースのクロストリジウム神経毒アッセイ |
Also Published As
Publication number | Publication date |
---|---|
US20090117572A1 (en) | 2009-05-07 |
CN1296712C (zh) | 2007-01-24 |
EP1543329A4 (en) | 2006-10-18 |
IL167410A (en) | 2011-12-29 |
CA2500040A1 (en) | 2004-04-08 |
US20040072270A1 (en) | 2004-04-15 |
AU2009222589B2 (en) | 2011-12-22 |
NO20051049L (no) | 2005-06-21 |
MXPA05003128A (es) | 2005-06-22 |
NO20051049D0 (no) | 2005-02-25 |
US20070122858A1 (en) | 2007-05-31 |
CN1685234A (zh) | 2005-10-19 |
CA2500040C (en) | 2014-12-23 |
CO5721032A2 (es) | 2007-01-31 |
JP4554369B2 (ja) | 2010-09-29 |
ZA200501500B (en) | 2005-10-26 |
EP1543329B1 (en) | 2016-08-03 |
AU2003282790A1 (en) | 2004-04-19 |
BR0314795A (pt) | 2005-07-26 |
DK1543329T3 (en) | 2016-12-05 |
US7749759B2 (en) | 2010-07-06 |
EP1543329A2 (en) | 2005-06-22 |
WO2004029576A2 (en) | 2004-04-08 |
KR20050071506A (ko) | 2005-07-07 |
PL376103A1 (en) | 2005-12-12 |
AU2003282790B2 (en) | 2009-07-02 |
US7183066B2 (en) | 2007-02-27 |
WO2004029576A3 (en) | 2004-06-10 |
RU2005109385A (ru) | 2006-01-27 |
AU2009222589A1 (en) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4554369B2 (ja) | クロストリジウム毒素に関する細胞ベースの蛍光共鳴エネルギー転移(fret)アッセイ | |
CA2462686C (en) | Fret protease assays for clostridial toxins | |
US7709608B2 (en) | Substrates useful for FRET protease assays for botulinum serotype A/E toxins | |
AU2008201932B2 (en) | Fret protease assays for clostridial toxins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060825 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060825 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090806 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090806 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090819 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100430 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100510 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100615 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100714 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130723 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4554369 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |